Skip to main content

Table 1 In a multivariate analysis of recurrent breast cancer cases, the expression of YB-1 was better than HER-2 or ER in predicting events

From: Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

Prognostic marker

Patients with relapse

 

HR (95% CI)

P value

Nodal status

  

   Positive versus negative

1.951 (1.725 to 2.206)

1.7 × 10-26

Tumor size (cm)

  

   2 to 5

1.392 (1.227 to 1.579)

2.8 × 10-7

   >5

1.921 (1.227 to 2.445)

1.2 × 10-7

Grade

  

   III versus II versus I

1.300 (1.139 to 1.482)

9.6 × 10-5

Age (years)

  

   <50 versus ≥ 50

1.000 (0.878 to 1.139)

1.000

ER

  

   Positive versus negative

0.942 (0.816 to 1.087)

0.41

HER-2

  

   Positive versus negative

1.256 (1.066 to 1.479)

6.0 × 10-3

YB-1

  

   Positive versus negative

1.331 (1.169 to 1.516)

1.6 × 10-5

  1. The predictive power of YB-1 was similar to that of tumor grade and smaller tumor size, but not as great as that of nodal status. CI, confidence interval; ER, estrogen receptor; HER, human epidermal growth factor receptor; HR, hazard ratio; YB-1 = Y-box binding protein-1.